138 related articles for article (PubMed ID: 17613777)
1. Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Takahashi H; Shinbo Y; Hasegawa A; Saitoh T; Tanaka R
Leuk Lymphoma; 2007 Jul; 48(7):1429-33. PubMed ID: 17613777
[No Abstract] [Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Lignon J; Sibon D; Madelaine I; Brice P; Franchi P; Briere J; Mounier N; Gisselbrecht C; Faure P; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):262-9. PubMed ID: 20709662
[TBL] [Abstract][Full Text] [Related]
4. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
5. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
[No Abstract] [Full Text] [Related]
6. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
7. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
8. R-DHAP: a good small step, but not the journey's end.
McLaughlin P; Vose JM
Leuk Lymphoma; 2008 Jun; 49(6):1019-21. PubMed ID: 18452108
[No Abstract] [Full Text] [Related]
9. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Geyer SM; Kurtin PJ; Colgan JP; Inwards DJ; Micallef IN; LaPlant BR; Michalak JC; Salim M; Dalton RJ; Moore DF; Reeder CB;
Leuk Lymphoma; 2008 Jun; 49(6):1074-80. PubMed ID: 18569634
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
11. A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Hong SJ; Kim JS; Chang JH; Kim KM; Kim SJ; Lee HW; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2009 Apr; 50(2):280-3. PubMed ID: 19430564
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
13. Improving second-line therapy in aggressive non-Hodgkin's lymphoma.
Gisselbrecht C; Mounier N
Semin Oncol; 2004 Feb; 31(1 Suppl 2):12-6. PubMed ID: 15042529
[TBL] [Abstract][Full Text] [Related]
14. Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Milojkovic D; Mijovic A; Taylor CG; Mufti GJ; Pagliuca A
Br J Haematol; 2000 Sep; 110(4):1013-4. PubMed ID: 11054097
[No Abstract] [Full Text] [Related]
15. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
16. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz MJ; McLemore M; Winton E; Jaye DL; Lonial S; Khoury HJ
Leuk Lymphoma; 2012 Apr; 53(4):725-7. PubMed ID: 21888615
[No Abstract] [Full Text] [Related]
18. Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
Schirmbeck NG; Mey UJ; Olivieri A; Ko YD; Kaiser U; Flieger D; Witzens-Harig M; Schmidt-Wolf IG
Cancer Invest; 2016 Sep; 34(8):361-72. PubMed ID: 27635469
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
